Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Clinical Trial of of VAR 200 (2-hydroxypropyl-ß-cyclodextrin, or HPßCD) in Adult Patients with Focal Segmental Glomerulosclerosis (FSGS)

Next Previous
Trial Profile

A Phase 2a Clinical Trial of of VAR 200 (2-hydroxypropyl-ß-cyclodextrin, or HPßCD) in Adult Patients with Focal Segmental Glomerulosclerosis (FSGS)

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Hydroxypropyl betadex (Primary)
  • Indications Focal segmental glomerulosclerosis
  • Focus Therapeutic Use
  • Sponsors ZyVersa Therapeutics

    • Most Recent Events

    • 25 Sep 2019 According to an ZyVersa Therapeutics media release, this study is expected to be initiated by end of 2019.
    • 03 Dec 2018 According to a Variant Pharmaceuticals media release, the company has secured $10 Million in financing from Korean company, Incon, in exchange for equity ownership. The funding will be used for the execution of this trial.
    • 24 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top